PRJNA273745
Plasmodium falciparum Dd2 Genome sequencing
Triaminopyrimidines (TAPs) emerged from a phenotypic screen against blood stages of P. falciparum. The clinical candidate is efficacious in a mouse model of P. falciparum infection and has a potential for single dose treatment in humans. WGS analysis implicates a novel, genetic determinant of resistance to TAPs.